BioCentury
ARTICLE | Financial News

Checkmate raises $22M as Krieg hands off CEO role

December 14, 2018 7:15 PM UTC

Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) said on Dec. 12 it completed a $22 million extension of its series B round and hired Barry Labinger to succeed co-founder Arthur Krieg as president and CEO.

New investor Decheng Capital led the round, with participation from existing investors Sofinnova Ventures, venBio and F-Prime Capital. The new funds bring the round to $49 million...

BCIQ Company Profiles

Checkmate Pharmaceuticals Inc.

BCIQ Target Profiles

Toll-like receptor 9 (TLR9)